GSK plc
Close on Oct 19, 2026
About GSK
Pharmaceutical Preparations, SIC 2834
GSK operates commercial operations and research and development divisions focused on specialty medicines, general medicines, and vaccines. The company develops and markets pharmaceutical treatments across multiple therapeutic areas, including human immunodeficiency virus (HIV), oncology, respiratory ailments, immunology, and inflammation. In addition, its portfolio features preventative vaccines for conditions such as shingles, meningitis, respiratory syncytial virus (RSV), and influenza. Its customer base includes commercial pharmaceutical wholesalers.
The company's geographic operations and reported geographical groupings encompass the United Kingdom, the United States, Belgium, broader European territories, and other international jurisdictions. The excerpted text provides segment and regional classifications across these markets but does not disclose specific facility counts, headquarters location, or administrative base information.
Summary of the business section of GSK's latest annual report, written by StockData.
Company profile
Company
- Legal name
- GSK plc
- Founded
- 2000
- Headquarters
- London, United Kingdom
- Address
- 79 New Oxford Street WC1A 1DG
- Phone
- 44 20 8047 5000
- Website
- www.gsk.com
- Employees
- 500,000, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- X0
- Auditor
- Deloitte LLP, London, United Kingdom
Stock & identifiers
- Ticker
- GSK
- Other tickers
- GLAXF
- Exchange
- NYSE
- IPO date
- Mar 28, 1980
- Shares outstanding
- 4.32B, Dec 31, 2025
- Filer category
- Large accelerated filer
- Stock splits
- 1-for-1.25 reverse, Mar 10, 2023; 1-for-1.25 reverse, Jul 19, 2022; 2-for-1, Nov 12, 1991; 2-for-1, Jan 27, 1986; 2-for-1, Feb 23, 1983
- SEC CIK
- 1131399
- CUSIP
- 37733W204
- ISIN
- US37733W2044
- LEI
- 5493000HZTVUYLO1D793
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
No recent ownership filings by officers or directors
GSK's leadership is listed in its proxy statement (Form DEF 14A).
Employees
Headcount reported in annual reports
“1 in 500,000 people worldwide, with most patients”
Corporate history
Events identified from SEC filings